Seeking Alpha: Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, ...
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
pharmaphorum: Innovative direct delivery strategies to unlock oligonucleotide therapeutics for CNS disorders
Yahoo Finance: BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
The American Journal of Managed Care: CNS Metastases in EGFR-Mutant NSCLC: Emerging Therapeutic Strategies and Ongoing Challenges
CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...
CNS-3D Brain Organoids Predict Clinical Seizure Liability Central nervous system (CNS) toxicity accounts for 25% of safety failures across drug discovery a | Drug Discovery And Development ...
The American Journal of Managed Care: CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications
CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
Secondary CNS lymphoma happens when non-Hodgkin’s lymphoma spreads to the brain, spinal cord, or eyes. Its symptoms depend on the areas of the CNS that are affected. The outlook for people with this ...